<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985036</url>
  </required_header>
  <id_info>
    <org_study_id>MGH-VEGF-1</org_study_id>
    <nct_id>NCT00985036</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients</brief_title>
  <official_title>Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marquette General Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Upper Michigan Brain Tumor Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Marquette General Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF)
      circulating in the blood stream of patients diagnosed with either a meningioma or a glioma.
      The questions that will be addressed include:

        1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?

        2. Is the VEGF level an indicator of the response to treatment?

        3. Does the VEGF level correlate with tumor histology and behavior?

        4. Is there a relationship between VEGF level and outcome?
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if VEGF levels correlate with tumor progression or recurrence</measure>
    <time_frame>every one to three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine if the VEGF level is an indicator of the response to treatment.</measure>
    <time_frame>Every one to three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if the VEGF level correlates with tumor histology and behavior.</measure>
    <time_frame>Every one to three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if there is a relationship between VEGF level and outcome.</measure>
    <time_frame>Every one to three months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Glioma</condition>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>Glioma</arm_group_label>
    <description>patients who are diagnosed with and are being treated for glioma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meningioma</arm_group_label>
    <description>patients who are diagnosed with and are being treated for meningioma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test</description>
    <arm_group_label>Glioma</arm_group_label>
    <arm_group_label>meningioma</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to Marquette General Hospital with a probable or confirmed diagnosis of
        meningioma or glioma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any patient presenting with glioma or meningioma

        Exclusion Criteria:

          -  a different type of brain tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Rovin, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upper Michigan Brain Tumor Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert J Winn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Michigan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suresh Nukala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marquette General Health Systems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marquette General Hospital</name>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <zip>49855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <last_update_submitted>April 20, 2012</last_update_submitted>
  <last_update_submitted_qc>April 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marquette General Health System</investigator_affiliation>
    <investigator_full_name>Richard A. Rovin, MD FACS</investigator_full_name>
    <investigator_title>Neurosurgeon</investigator_title>
  </responsible_party>
  <keyword>glioma</keyword>
  <keyword>meningioma</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

